Combinatorial Effects of miRNAs in HSV-2 Infection of Macrophages: An In Silico and In Vitro Integration Approach.

HSV-2 combinatorial inflammation microRNA network biology signaling therapeutics

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
14 Sep 2023
Historique:
received: 15 08 2023
revised: 05 09 2023
accepted: 07 09 2023
medline: 28 9 2023
pubmed: 28 9 2023
entrez: 28 9 2023
Statut: epublish

Résumé

The rising issues of herpes simplex virus (HSV)-2 drug ramifications have encouraged the researchers to look for new and alternative approaches that pose minimum adversities in the host while efficiently reducing the HSV-2 infection. Although microRNAs (miRNAs), as unorthodox approaches, are gaining popularity due to eliciting highly reduced immunogenic reactions, their implications in HSV-2 research have been rarely explored. In this study, a pool of cellular miRNAs with significance in HSV-2-induced inflammatory and immune responses have been identified. Computationally recognizing the host targets of these miRNAs through network biology and machine learning, in vitro validation has been addressed along with the identification of their regulation in the HSV-2 infection. To signify the role of these identified miRNAs, they have been individually ectopically expressed in macrophages. The ectopic expression of the individual miRNAs was able to suppress HSV-2 viral gene expression. Taking a step forward, this study also highlights the Box-Behnken design-based combinatorial effect of ectopically expressed miRNAs on maximum suppression of HSV-2 infectivity. Therefore, the concentrations of each of the miRNAs optimized in a combination, predicted through expert systems biology tools were validated in vitro to not only recover the target expressions but also inhibit the HSV-2 infection in the macrophages. Overall, the study offers miRNAs as intriguing alternatives to commercially available medications against HSV-2. Moreover, the study illuminates the prophylactic potentiality of the miRNAs, which is significant since there are currently no vaccines available for HSV-2. Moving forward, the miRNAs are employed in an innovative strategy that incorporates intricate biological system models and in vitro confirmation methods to deliver a prospective combinatorial miRNA therapeutic against HSV-2 infection.

Identifiants

pubmed: 37766164
pii: vaccines11091488
doi: 10.3390/vaccines11091488
pmc: PMC10537408
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Department of Science and Technology, Science and Engineering Research Board (DST-SERB)
ID : CRG/2021/000190
Organisme : Department of Health Research, Young Scientist Grant (DHR-YSS)
ID : YSS/2020/000010/PRCYSS

Références

PLoS One. 2014 Aug 12;9(8):e104113
pubmed: 25117537
Front Genet. 2019 May 16;10:478
pubmed: 31156715
Int J Mol Sci. 2020 Jan 04;21(1):
pubmed: 31947962
Mol Pharmacol. 2003 Sep;64(3):557-69
pubmed: 12920191
J Immunol. 2017 Feb 1;198(3):1006-1014
pubmed: 28115590
Noncoding RNA. 2018 Nov 23;4(4):
pubmed: 30477082
Anal Chim Acta. 2007 Aug 6;597(2):179-86
pubmed: 17683728
Bull World Health Organ. 2020 May 01;98(5):315-329
pubmed: 32514197
Nucleic Acids Res. 2020 Jan 8;48(D1):D127-D131
pubmed: 31504780
Viruses. 2023 Feb 03;15(2):
pubmed: 36851643
F1000Res. 2018 Oct 31;7:
pubmed: 30443341
Cancer Treat Rev. 2004 Apr;30(2):193-204
pubmed: 15023437
Int J Mol Sci. 2019 Jun 01;20(11):
pubmed: 31159424
Cell Prolif. 2020 Dec;53(12):e12949
pubmed: 33140889
Saudi J Biol Sci. 2021 Apr;28(4):2581-2590
pubmed: 33911969
Viruses. 2016 Jun 02;8(6):
pubmed: 27271654
J Med Virol. 2017 Jun;89(6):1069-1079
pubmed: 27813118
Oncol Lett. 2018 Mar;15(3):3998-4004
pubmed: 29556282
Immunobiology. 2014 Jan;219(1):64-77
pubmed: 24028839
Exp Cell Res. 2004 Jun 10;296(2):196-207
pubmed: 15149850
Cell Signal. 2020 Oct;74:109716
pubmed: 32707074
Sci Rep. 2017 Dec 21;7(1):17972
pubmed: 29269892
Virology. 1994 May 1;200(2):598-612
pubmed: 8178446
Eur J Pharmacol. 2020 Mar 15;871:172910
pubmed: 31926991
Int Immunopharmacol. 2014 Nov;23(1):37-45
pubmed: 25130606
Antiviral Res. 2020 May;177:104714
pubmed: 32165083
Genome Biol. 2003;4(5):P3
pubmed: 12734009
Viruses. 2020 Sep 23;12(10):
pubmed: 32977414
J Ethnopharmacol. 2020 May 23;254:112611
pubmed: 32088246
PLoS Pathog. 2011 Jun;7(6):e1002109
pubmed: 21738472
Transplantation. 2009 Mar 27;87(6):821-4
pubmed: 19300183
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Virology. 2015 May;479-480:568-77
pubmed: 25798530
PLoS One. 2015 Apr 09;10(4):e0124903
pubmed: 25856395
Cold Spring Harb Perspect Biol. 2012 Sep 01;4(9):a011189
pubmed: 22952397
Cell Adh Migr. 2020 Dec;14(1):227-241
pubmed: 32990143
Biomed Pharmacother. 2018 Jan;97:1409-1416
pubmed: 29156530
J Immunol. 2001 Oct 15;167(8):4436-42
pubmed: 11591769
Nature. 1994 Aug 18;370(6490):527-32
pubmed: 8052307
RNA. 2008 Jun;14(6):1012-7
pubmed: 18426918
J Glob Antimicrob Resist. 2020 Dec;23:370-376
pubmed: 33161114
Sci Rep. 2016 Aug 11;6:31302
pubmed: 27509841
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Acta Pharmacol Sin. 2017 Mar;38(3):402-414
pubmed: 28112176
J Virol. 2013 May;87(10):5904-15
pubmed: 23487471
J Immunol. 2015 Apr 1;194(7):3102-15
pubmed: 25712217
Chemosphere. 2020 Sep;255:126913
pubmed: 32402875
J Virol. 2015 Mar;89(5):2456-8
pubmed: 25540363
J Virol. 2022 May 11;96(9):e0034922
pubmed: 35404085
Oncogene. 2003 Dec 8;22(56):8983-98
pubmed: 14663477
PLoS Pathog. 2020 Oct 14;16(10):e1008900
pubmed: 33052961
Int J Mol Sci. 2019 Dec 24;21(1):
pubmed: 31878223
J Immunol. 2015 Jan 15;194(2):584-94
pubmed: 25512602
Kaohsiung J Med Sci. 2021 Mar;37(3):200-207
pubmed: 33058411
BMC Infect Dis. 2010 Mar 09;10:59
pubmed: 20214795
Antiviral Res. 2011 Mar;89(3):219-26
pubmed: 21291913

Auteurs

Anwesha Banerjee (A)

Division of Virology, ICMR-National AIDS Research Institute, Pune 411026, MH, India.

Debashree Dass (D)

Division of Virology, ICMR-National AIDS Research Institute, Pune 411026, MH, India.

Kishore Dhotre (K)

Division of Virology, ICMR-National AIDS Research Institute, Pune 411026, MH, India.

Pooja Wakchoure (P)

Division of Microbiology, ICMR-National AIDS Research Institute, Pune 411026, MH, India.

Ashwini More (A)

Division of Virology, ICMR-National AIDS Research Institute, Pune 411026, MH, India.

Santanu Rana (S)

Department of Zoology, RPMC-University of Calcutta, Uttarpara 712258, WB, India.

Abdul A Khan (AA)

Division of Microbiology, ICMR-National AIDS Research Institute, Pune 411026, MH, India.

Anupam Mukherjee (A)

Division of Virology, ICMR-National AIDS Research Institute, Pune 411026, MH, India.

Classifications MeSH